Other genetic markers identified as possible mediators of selinexor sensitivity include ABCC4 (MRP4) [94] and ASB8 (ankyrin repeat and SOCS box containing 8), the latter potentially representing a shared modulator of activity across cancer types [95] associated with ASB8 promoting selinexor‐induced proteasomal degradation of XPO1 [95]. The gene discussed is XPO1; the disease is cancer.